Evaluation of the Effect of an Advance Diabetes Support Product Targeting the Improved β-Cell Functions and β-Cell Regeneration for the Management of Diabetes Mellitus

Aim: Diabetes support product (ADSP) with phytocompounds was proposed to improve insulin secretion, avoid pancreatic beta cell apoptosis, and moderate beta cell differentiation and proliferation. In this research work, beta cell regenerative potential of ADSP was evaluated with STZ induced diabetes in rodents. Method: Single dose of Streptozotocin (STZ) (70mpk; i.p.) was used to induce diabetes in the Wistar rats. The treatment of vehicle or test or GLB was continued for the next 28 days to assess sub-acute anti-diabetic potential. Fasting blood glucose levels (BGL) was monitored weekly once throughout the experiment. Bodyweight, Feed-water consumption was calculated on every day till end of the experiment. Interleukin-6, Interleukin-1β and Interferon-γ was also analysis from blood serum after 28 days of treatment in rats. Further, animal was humanely sacrifice and organs such as liver, kidney(s) and pancreas were isolated for histopathology analysis. Result: Research showed that Insulin is Increased by 3 times in comparison with the diabetic group by ADSP after 28 days. After 28 days treatment of ADSP to rodents, Interleukin-6 decreased by 52%, Interleukin-1β decreased by 73% and Interferon-γ decreased by 28% in comparison with the diabetic control group. It is also observed in histopathology studies that there was a rise in the quantity of islets after 28 days treatment of ADSP in Streptozotocin carried diabetic rats. Conclusion: Hence in conclusion, advance diabetes support product supposed to be appreciated as synergistic product of encouraging the β-cell regeneration in vivo.